Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Lancet Digit Health 2020
In this multicentre cohort study following more than 1·3 million patients with hypertension from the USA and Spain, we observed no clear association of increased risk of COVID-19 diagnosis, hospital admission, or subsequent complications associated with the outpatient prevalent ACEI or ARB use. Our findings support recent regulatory and clinical society recommendations that patients should not halt their ACEI or ARB therapy despite previously posited mechanisms of increased COVID-19 risk.